| Identification | Back Directory | [Name]
Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(5-fluoro-2-methylphenyl)-4,6-dihydro-6,6-dimethyl-3-[[[1-(trimethylsilyl)cyclobutyl]carbonyl]amino]- | [CAS]
2055741-39-2 | [Synonyms]
IV-361
Pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide, N-(5-fluoro-2-methylphenyl)-4,6-dihydro-6,6-dimethyl-3-[[[1-(trimethylsilyl)cyclobutyl]carbonyl]amino]- | [Molecular Formula]
C23H32FN5O2Si | [MOL File]
2055741-39-2.mol | [Molecular Weight]
457.62 |
| Chemical Properties | Back Directory | [Boiling point ]
660.7±55.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 90 mg/mL (196.67 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.47±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1)[1].
IV-361 has less inhibition on CDK2 (Ki≥1000 nM) or PLK1 (Ki≥5000 nM)[1]. IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC50≤100 nM) in periphery blood mononuclear cell (PBMC)[1]. IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI50≤100 nM)[1].
IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116[1]. | [References]
[1]. Noriaki Iwase, et al. Substituted dihydropyrrolopyrazole derivative. US20190256531A1. |
|
|